Remedica

About Remedica

Remedica is a leading pharmaceutical company with export activities in more than 160 countries. Originally founded in 1960 by Mr. Takis Pattichis, Remedica specializes in the development, production, and sale of high-quality, safe, and efficacious pharmaceutical products for human use. Furthermore, Remedica offers out-licensing opportunities, and its product portfolio consists of antineoplastic agents, antivirals, aromatase inhibitors, anti-infectives, products for the nervous system, products for the cardiovascular system, dermatologicals, and antimalarials, and has a pipeline consisting of more therapeutic categories. Currently, Remedica has 5 state-of-the-art factories, all of which have been routinely inspected and approved by the health authorities of several European Union Member States, including Cyprus, Germany, and Denmark, as well as those of the United Kingdom, Russia, Australia (TGA), Brazil (ANVISA), Japan (PMDA), and many more. Remedica invests in product development, innovation, technology, and human resources, and encourages the progress of science, education, and health. Remedica’s Corporate Social Responsibility (CSR) commitment is built on its vision, strategies, and mission. It is based on its core business, operating background, stakeholder’s outlooks, and company’s culture. By providing safe, efficacious, and high-quality pharmaceuticals at affordable prices, Remedica has improved the health and saved the lives of millions of people who may otherwise have had to pay more or who may not have been in a position to afford a more expensive treatment. To meet this commitment, the company implements management systems in its operations that accord with the requirements of its CSR standards. Remedica’s CSR is based on various parameters, which include but are not limited to environment, human resources, society, and education.